Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, July 16, 2018
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
Fri, July 13, 2018
[ Fri, Jul 13th 2018
] - WOPRAI
[ Fri, Jul 13th 2018
] - WOPRAI
[ Fri, Jul 13th 2018
] - WOPRAI
[ Fri, Jul 13th 2018
] - WOPRAI
Matthew Harrison Maintained (BIIB) at Buy with Decreased Target to $366 on, Jul 13th, 2018
Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $369 to $366 on, Jul 13th, 2018.
Matthew has made no other calls on BIIB in the last 4 months.
There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Skorney of "Baird" Downgraded from Buy to Hold on, Tuesday, July 10th, 2018
- Geoff Meacham of "Barclays" Downgraded from Buy to Hold on, Thursday, April 5th, 2018
These are the ratings of the 2 analyists that currently disagree with Matthew
- Robyn Karnauskas of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $371 on, Friday, July 6th, 2018
- Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy on, Thursday, May 31st, 2018
